Avenzo Therapeutics and DualityBio Announce Exclusive Global License for Potential Best-In-Class EGFR/HER3 Antibody-Drug Conjugate ...

EGFR BATs is under clinical development by Transtarget and currently in Phase I for Gliosarcoma. According to GlobalData, Phase I drugs for Gliosarcoma does not have sufficient historical data to ...

EGFR BATs is under clinical development by Transtarget and currently in Phase I for Glioblastoma Multiforme (GBM).

A panelist discusses how infusion-related reactions to monoclonal antibodies in EGFR-mutated NSCLC can be effectively managed ...

Patients with advanced lung tumors harboring EGFR exon 19 deletions or exon 21 L858R mutations are eligible for the combo treatment.

Objective Both belimumab and telitacicept are recognised blockers for B lymphocyte activation, both of which have been ...

Cetuximab, an EGFR antibody, was recently shown to improve survival when added to chemotherapy in the first-line treatment of advanced NSCLC. Tumor Markers of Response Somatic mutations in EGFR ...

MabGenesis, a biotechnology company specializing in antibody drug development, announced on the 24th that it has raised 470 million yen (approximately $3.2 million) in its latest funding round.

Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that it will participate in and ...

EGFR磷酸化的位置、程度对于生理病理来说都有重要意义。而在研究蛋白的磷酸化位置、程度过程中，磷酸化抗体是一件科研利器。 产品数据： 下面以Phospho-EGF Receptor (Tyr1068) Antibody, Rabbit MAb （Cat: 110463-R0027）为例为大家介绍。 内源性验证 对于磷酸化本底较低的 ...

Blots were incubated for 1 h at room temperature with goat polyclonal anti-Reg4 antibody (1:200 dilution), rabbit polyclonal anti-EGFR (1:1000 dilution) and p-EGFR (1:1000 dilution), rabbit monoclonal ...